Next Article in Journal
Salinity-Induced Variation in Biochemical Markers Provides Insight into the Mechanisms of Salt Tolerance in Common (Phaseolus vulgaris) and Runner (P. coccineus) Beans
Next Article in Special Issue
Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer
Previous Article in Journal
Recent Advances in Antimicrobial Polymers: A Mini-Review
Previous Article in Special Issue
Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation
Review

Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back

1
Axencia Galega de Coñecemento en Saúde (ACIS), SERGAS, Avda, Fernando de Casa Novoa, Santiago de Compostela 15707, Spain
2
London Regional Cancer Program, London Health Sciences Centre, London, ON N6A 4L6, Canada
3
Translational Medical Oncology/Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Trav. Choupana s/n, Santiago de Compostela 15706, Spain
*
Authors to whom correspondence should be addressed.
Academic Editor: Dario Marchetti
Int. J. Mol. Sci. 2016, 17(9), 1580; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17091580
Received: 2 July 2016 / Revised: 5 September 2016 / Accepted: 9 September 2016 / Published: 20 September 2016
(This article belongs to the Special Issue Circulating Tumor Cells)
Prostate cancer is the most common cancer in men worldwide. To improve future drug development and patient management, surrogate biomarkers associated with relevant outcomes are required. Circulating tumour cells (CTCs) are tumour cells that can enter the circulatory system, and are principally responsible for the development of metastasis at distant sites. In recent years, interest in detecting CTCs as a surrogate biomarker has ghiiukjrown. Clinical studies have revealed that high levels of CTCs in the blood correlate with disease progression in patients with prostate cancer; however, their predictive value for monitoring therapeutic response is less clear. Despite the important progress in CTC clinical development, there are critical requirements for the implementation of their analysis as a routine oncology tool. The goal of the present review is to provide an update on the advances in the clinical validation of CTCs as a surrogate biomarker and to discuss the principal obstacles and main challenges to their inclusion in clinical practice. View Full-Text
Keywords: prostate cancer; circulating tumour cells; tumour markers; precision oncology prostate cancer; circulating tumour cells; tumour markers; precision oncology
Show Figures

Figure 1

MDPI and ACS Style

León-Mateos, L.; Vieito, M.; Anido, U.; López López, R.; Muinelo Romay, L. Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back. Int. J. Mol. Sci. 2016, 17, 1580. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17091580

AMA Style

León-Mateos L, Vieito M, Anido U, López López R, Muinelo Romay L. Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back. International Journal of Molecular Sciences. 2016; 17(9):1580. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17091580

Chicago/Turabian Style

León-Mateos, Luis, María Vieito, Urbano Anido, Rafael López López, and Laura Muinelo Romay. 2016. "Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back" International Journal of Molecular Sciences 17, no. 9: 1580. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17091580

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop